Citeline Clinical’s Post

GLP-1 receptor agonists, like semaglutide, should be considered Schedule III controlled substances, just like testosterone: General practitioners are not always adequately trained to prescribe GLP-1 medications, leading to widespread off-label use for weight loss, even in individuals without clinical obesity. Similar to testosterone, which is controlled due to potential misuse, GLP-1 drugs need stricter regulation to prevent overprescription, especially by providers lacking specialized knowledge in managing these powerful medications. Classifying GLP-1s as Schedule III would ensure that only trained specialists handle these prescriptions, protecting patients from inappropriate use and reducing the risks of adverse effects. #GLP1 #ControlledSubstances #HealthRegulation #MedicationSafety #PatientCare #Pharmacy #SpecialistCare

APELOA has obtained FDA approval for our Metoprolol Succinate Extended-Release Tablets. This milestone underscores our capability to bring the U.S. market high-quality medication, reinforcing our commitment to global healthcare. Metoprolol Succinate, a selective β1 receptor blocker, is essential in treating hypertension, angina, and chronic heart failure. Our product's FDA approval follows its successful NMPA clearance in 2021 and recognition in China's national drug procurement, enhancing our market presence and brand reputation. The recent zero-defect PAI by the U.S. FDA at our international manufacturing facility in 2023 is a testament to our stringent quality standards. APELOA continues to drive our internationalization strategy, dedicated to bringing more innovative formulations to the global market, aiming to improve medication safety and accessibility for patients worldwide. #Apeloa #FDF #FDAApproval #MetoprololSuccinate #GlobalHealth #PharmaceuticalInnovation

Has your organization been noodling on this decision? Join our webinar tomorrow for a discussion about to cover or not to cover. Have additional questions on the topic? We are here to help! Direct message me and we can have a confidential conversation. #benefitsconsulting #strategy #employeehealthandbenefits #pharmacyconsulting

Know this clinical pearl to avoid conflict if you’re about to order a drug screen for a patient on Butrans. 📌: https://lnkd.in/eJQbRwr4 As the use of buprenorphine for pain management grows, understanding how to interpret urine drug screens for buprenorphine becomes increasingly important. Butrans, a low dose transdermal buprenorphine formulation, doesn’t always show up positive in urine drug tests. In fact, nearly 1/3 of patients on Butrans in a study didn’t have high enough drug levels to be detected by confirmatory test, which is considered the gold standard for drug screening. So, if a drug test comes back negative for a patient on Butrans, it’s crucial to interpret the result carefully—considering clinical improvement, PDMP, and trust. ——————— 💊 Daily Pain Dose: What do we know about Belbuca then? #PainManagement #Opioids #OpioidStewardship

Study: Patients With Hypothyroidism Who Lost Weight on Semaglutide Saw Decreases in TSH Levels: These findings are significant in understanding interactions between glucagon-like peptide-1 medications and thyroid dysfunction because prior research has shown conflicting results. #finance #pharmacy #lifesciences

We're cheering on breakthroughs in Alzheimer's and dementia research and care, as we advocate for older adults to live as independently as possible for as long as possible. #EndAlzheimer's #DementiaCare #OlderAdults #MemoryCare #IndependentLiving

In our new article, we described the mechanism of the #incretin effect impairment. This will guide improved drug development for recovery of the incretin effect with less adverse effect. GLP1 agonists counter the impaired incretin effect without correcting its impairment. #obesity #ozempic #munjaro #diabetes International Diabetes Federation European Association for the Study of Diabetes e.V. (EASD) https://lnkd.in/eKGzSeuY

📢 Medication Update: SPRAVATO (esketamine) The Spravato package insert has been updated to include important information regarding cognitive and memory function. 🔹 Key Update: Long-term cognitive and memory impairment have been reported with repeated ketamine misuse or abuse. 🔹 Clinical Trial Findings: In 1-year and 3-year long-term, open-label clinical trials in adults, cognitive functioning with Spravato remained stable over time, as assessed by: Cogstate computerized battery Hopkins Verbal Learning Test-Revised (HVLT-R) This update provides valuable insights into the safety profile of Spravato for long-term use in adults. #Pharmacy #MedicationSafety #SpecialtyMedicationUpdate Resource: Spravato [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2024

GLP-1 agonists, used for managing type 2 diabetes and promoting weight loss, are experiencing growing interest among businesses. New trends bring new questions. How effective are these drugs and what do employers need to consider before adding them to their formulary? #EmployerBenefits #WeightLoss #RX #MarshMMA